

1 **Abstract**

2 **Background:** Estimating survival can aid care planning, but the use of absolute survival
3 projections can be challenging for patients and clinicians to contextualize. We aimed
4 to define how heart failure and its major comorbidities contribute to loss of actuarially
5 predicted life expectancy.

6 **Methods:** We conducted an observational cohort study of 1794 adults with stable
7 chronic heart failure and reduced left ventricular ejection fraction, recruited from
8 cardiology outpatient departments of 4 United Kingdom (UK) hospitals. Data from an
9 11-year maximum (5-year median) follow-up period (999 deaths) was used to define
10 how heart failure and its major comorbidities impact upon survival, relative to an age-
11 sex matched control UK population, using a relative survival framework.

12 **Results:** After 10 years, mortality in the reference control population was 29%. In
13 people with heart failure, this increased by an additional 37% (95% confidence interval
14 34-40%), equating to an additional 2.2-years of lost life, or a 2.4-fold (2.2-2.5) excess
15 loss of life. This excess was greater in men than women (2.4 years [2.2-2.7] versus
16 1.6 years [1.2-2.0]; $p < 0.001$). In patients without major comorbidity, men still
17 experienced excess loss of life, whilst women experienced less and were non-
18 significantly different from the reference population (1 year [0.6-1.5] versus 0.4 years
19 [-0.3-1]; $p < 0.001$). Accrual of comorbidity was associated with substantial increases in
20 excess loss of life, particularly for chronic kidney and lung disease.

21 **Conclusions:** Comorbidity accounts for the majority of lost life expectancy in people
22 with heart failure. Women, but not men, without comorbidity experience survival close
23 to reference controls.

24

1 **Background**

2 Chronic heart failure (CHF) is a common late phase in the natural history of many
3 cardiovascular diseases, affecting millions of people globally, and remains associated
4 with an appreciable mortality rate (1). In spite of declining age-sex adjusted incidence
5 rates, the prevalence of heart failure continues to increase (2), reflecting improving
6 survival rates and an ageing population. Hence, people with heart failure are
7 increasingly old and have a rising burden of major comorbidity (2). These trends pose
8 challenges for the estimation and communication of prognosis, with important
9 implications for patients and clinicians aiming to make well-informed decisions. For
10 example, established prognostication tools may be less reliable at predicting
11 remaining life expectancy in people over 80 (3), and do not convey the substantial risk
12 of death in similarly aged individuals without heart failure. Moreover, prognostic
13 estimates do not describe the relative contribution of heart failure versus associated
14 comorbidities, which may be important in defining therapeutic priorities in the growing
15 population with multimorbidity. Indeed, non-cardiovascular causes of death are
16 increasingly common in people with heart failure, especially with advancing age (4,5).
17 Furthermore, prior research has shown substantial discordance between patient-
18 predicted and prognostic model predicted survival, illustrating the need to better
19 communicate this important and sensitive topic (6). These issues suggest that
20 alternate approaches to considering and communicating prognosis may be helpful for
21 health professionals and people with heart failure. Therefore, we set out to describe
22 the survival of people with heart failure *relative* to an age-sex matched control
23 population and then define how comorbid disease contributes to the observed loss of
24 survival.

25

1 **Methods**

2 As described in our earlier publications (4), we conducted a prospective cohort study
3 with the pre-defined aim of identifying prognostic markers in patients with CHF and
4 reduced left ventricular ejection fraction (LVEF), receiving contemporary evidence-
5 based therapy. Inclusion in the study required the presence of stable signs and
6 symptoms of CHF for at least 3 months, age ≥ 18 years, and LVEF $\leq 45\%$ on
7 transthoracic echocardiography. Between June 2006 and December 2014,
8 consecutive patients attending specialist cardiology clinics (secondary and tertiary
9 referral) in four United Kingdom (UK) hospitals were approached, and 1794 patients
10 provided written informed consent. The Leeds West Research Ethics Committee gave
11 ethical approval and the investigation conforms to the principles outlined in the
12 *Declaration of Helsinki*.

13
14 Details of comorbid diabetes and chronic obstructive pulmonary disease (COPD) were
15 collected at recruitment, and symptomatic status was defined using the New York
16 Heart Association (NYHA) classification (4). Venous blood was collected at study
17 recruitment for assessment of renal function in the local hospital chemical pathology
18 laboratories. Estimated glomerular filtration rate (eGFR) was calculated using the
19 Modification of Diet in Renal Disease method, with chronic kidney disease (CKD)
20 stage 4 or worse being defined as $eGFR < 30 \text{ ml/minute/1.73m}^2$ (7). Two-dimensional
21 echocardiography was performed according to The American Society of
22 Echocardiography recommendations (8). Resting heart rate was measured using 12-
23 lead electrocardiograms. Prescribed doses of loop diuretics, angiotensin converting
24 enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB) and β -adrenoceptor
25 antagonists (β -blockers) were collected at study recruitment. Total daily doses of β -

1 blockers , ACEi (or ARB if used instead of ACEi) and loop diuretic were expressed
2 relative to the maximal licensed dose of bisoprolol, ramipril and furosemide,
3 respectively, as previously published (4). Receipt of cardiac resynchronisation therapy
4 (CRT) or implantable cardioverter-defibrillator (ICD) was assessed during the six-
5 month period after recruitment.

6
7 All patients were registered with the UK Office of Population Censuses and Surveys,
8 which provided details of time of death, with a final censorship date of 8th November
9 2018; maximum follow-up was for 11 years. Actuarial survival predictions were derived
10 from the United Kingdom National Life Tables (UK-NLT), an official survival estimation
11 measure produced by the UK government (9). The UK-NLT provide annual death rates
12 by sex and age for overlapping three-year periods, which we assigned the value to the
13 middle of the range: for example, the death rate for 2011-2013 is used with patients
14 recruited in 2012. This provides the baseline survival for members of the public with
15 this age and sex, which we used as a reference control population.

16

17 *Statistics*

18 Patient characteristics are reported using the mean and standard deviation for
19 continuous variables, with categorical variables summarised using the count of each
20 class and the percentage of the dataset it represents. Median survival rates and
21 Kaplan-Meier curves describing the absolute survival, stratified by sex, were produced
22 using the survival package in R (<https://CRAN.R-project.org/package=survival>).
23 Relative survival results were produced using the relsurv package within R
24 (<https://www.jstatsoft.org/article/view/v087i08>). In particular, we use relative survival
25 tables to investigate the excess loss of life associated with heart failure, both on the

1 entire cohort, stratified by sex, and on the subset of participants according to the
2 number of comorbidities. Wald confidence intervals are used for mortality rate, whilst
3 500 bootstrap samples are used to produce confidence intervals for years of life lost,
4 with a t-test to compare the means between sexes. To investigate the additional
5 impact of comorbidities, an additive relative survival model was produced using the
6 relsurv package within R. The presence of four major comorbidities (COPD, diabetes,
7 ischaemic aetiology, CKD grade ≥ 4) were used as independent variables. Excess
8 hazard ratios and Wald confidence intervals are reported, fit using the maximum
9 likelihood principle. A sensitivity analysis was performed to determine whether the
10 excess hazard due to heart failure is best modelled as constant or time-varying: we
11 compare a constant term with piecewise constant on one-year intervals and a
12 continuous variant fit using the expectation maximization approach.

13

14 **Results**

15 As described in **Table 1**, the study cohort had a mean age of 69.6 years and 73%
16 were male. The aetiology of heart failure was ischaemic heart disease in 59% of cases,
17 mean left ventricular ejection fraction was 32%, and 31% of people had moderate to
18 severe dyspnoea (NYHA classification 3 or 4). Major comorbidity was common, with
19 diabetes being present in 28%, COPD in 16%, and CKD grade ≥ 4 in 18%. After a
20 maximum follow-up period of 11 years (median 5-years), 999 (55.7%) deaths
21 occurred. As illustrated in **Figure 1A**, median survival was 6.6 years (95% confidence
22 interval 6.3 to 7 years). However, this illustrates a composite of the excess risk of
23 death in this cohort *plus* the background risk in the general population, which is likely
24 to be substantial in the context of their advanced age. To address this, we constructed
25 relative survival models that define the expected loss of survival in the background

1 population, and therefore the excess risk in the study cohort (**Figure 1B**). After 10
2 years, the expected background population mortality rate is 28.6% (95% confidence
3 interval [CI] 27.8-29.4%); in addition to this, our study cohort experienced an excess
4 risk of 37% (95% CI 33.6-40.5%). Expressed as years of life lost over 10 years of
5 follow-up, the expected loss accounts for 1.6 (95% CI 1.54-1.72) years, whilst the
6 excess risk accounts for a further 2.2 (95% CI 1.99-2.41) years, resulting in a
7 cumulative loss of 3.8 (95% CI 3.66-4.0) years. Therefore, our study cohort lost 2.4-
8 fold (95% CI 2.2-2.5) more life than expected.

9
10 Next we explored the impact of male sex, given its established role as an adverse
11 prognostic factor. Relative survival curves for our cohort stratified by sex are given in
12 **Figure 2**. When the expected background and excess mortality were defined with
13 relative survival tables, men and women exhibited similar 10-year background
14 mortality rates (27.9% [26.9-28.9%] versus 30.5% [29-32.1%]). However, excess 10-
15 year mortality rates were higher in men than women (40.3% [36.3-44.2%] versus 28%
16 [21-35.1]). Over 10-years of follow-up, the background loss of life was 1.6 years in
17 both men and women, but the excess risk was 2.4 (95% CI 2.2-2.7) years in men
18 versus 1.6 (95% CI 1.2-2.0) years in women, resulting in an average cumulative loss
19 of 4 and 3.2 years, respectively. Therefore, men and women lost 2.5-fold (95% CI 2.3-
20 2.7) and 2-fold (95% CI 1.7-2.3) more life than expected, respectively, suggesting male
21 sex is associated with a higher-risk heart failure phenotype ($p < 0.001$).

22
23 Given the differing comorbidity profile of men and women (**Table 1**), we next explored
24 how they might contribute to the differential loss of expected life in these groups. As
25 illustrated in **Figure 3**, men and women with increasing numbers of comorbidities

1 experienced substantially greater loss of life expectancy. Indeed, in patients with 3 or
2 more comorbidities, men lost an excess of 4.6 years (95% CI 3.1-5.5), whilst women
3 lost an excess of 3.1 years (95% CI 1.9-4). Importantly, in patients without major
4 comorbidity, men still experienced excess loss of life, whilst women experienced less
5 and were non-significantly different from the reference population (1 year [95% CI 0.6
6 to 1.5] versus 0.4 years [95% CI -0.3 to 1]; $p < 0.001$). To explore the contribution of
7 specific comorbidities to loss of expected life, a multivariate Cox regression analysis
8 was performed and the excess hazard ratios (EHRs) are presented in **Table 2**. All of
9 these were associated with loss of expected life, but with substantial heterogeneity in
10 their effect size. Notably, whilst statistically significant, the baseline excess hazard was
11 small and approximately constant for the duration of the study; this implies that the
12 excess risk associated with heart failure *per se* remained broadly constant. Moreover,
13 sensitivity analyses using various approaches to allow time-variance in the baseline
14 excess hazard did not reveal differences in the EHRs of the main comorbidities.

15

16 **Discussion**

17 By considering survival relative to actuarial estimates of life expectancy, we have
18 shown that heart failure is associated with a 2.4-fold greater loss of time alive than
19 observed in the age-sex matched general population over ten years. Notably, male
20 sex and accrual of major comorbidities are associated with larger loss of life, whilst
21 women without major comorbidity have life expectancy compatible with actuarial
22 projections. This approach to defining survival may provide useful perspective for
23 clinicians considering the magnitude of risk posed by heart failure in the context of an
24 aging and increasingly multimorbid population. This context may be particularly useful

1 when communicating risk to people with heart failure, who often struggle to estimate
2 their own prognosis.

3

4 *Estimating prognosis*

5 Validated tools, such as the Seattle Heart Failure Model (SHFM) and the Meta-
6 analysis Global Group in Chronic Heart Failure (MAGGIC) score (10,11), are already
7 available to estimate the prognosis of people with heart failure in terms of absolute
8 lifespan. Whilst valuable, it is important to ask whether this approach tells patients and
9 clinicians what they want to know. By overlooking the inevitability of death in similar
10 people without disease, such prognostic estimates may be misinterpreted, resulting in
11 poorly informed decision making. The challenges of prognostication in people with
12 heart failure are illustrated by the discordance between model- and patient-estimated
13 absolute life expectancy (6). By considering survival relative to actuarially predicted
14 life expectancy, we hope that our approach will provide essential context to aid the
15 challenging process of communicating prognosis. This may take the form of ‘ballpark’
16 estimates of excess loss of life for groups of similar people, or by developing an
17 individualised prognostication tool, such as the SHFM. Further research is needed to
18 address the validity, acceptability, and added value of this approach, but we think that
19 it has the potential to improve prognostication in clinical practice.

20

21 *Multimorbidity as risk marker and therapeutic target*

22 Recent research describing all people with heart failure in a representative cohort of 4
23 million UK residents found that multimorbidity is becoming increasingly common (2).
24 Whilst we focussed on just four major comorbidities, 26% of our cohort were not
25 multimorbid (i.e. heart failure with at least one comorbidity), and 31% had 2 or more

1 of these comorbidities. Strikingly, people with 3 or more comorbidities experienced
2 approximately 5-fold greater excess loss of life than people with no comorbidity
3 (**Figure 3**). This suggests that the accumulation of comorbidity is an important part of
4 the adverse prognostic impact of heart failure. Optimal medical therapy is associated
5 with substantial reductions in heart failure morbidity and lifespan extension in clinical
6 trial participants (12), yet clinical trials often exclude multimorbid people. These data
7 highlight the need to design clinical trials specifically recruiting people with heart failure
8 and multimorbidity, possibly applying complex interventions that target more than just
9 the heart failure syndrome.

10

11 *Heart failure in men and women*

12 Poorer survival of men has been observed in many studies of heart failure, and is
13 accounted for in the SHFM and MAGGIC prognostic models (10,11). Whilst this could
14 to some extent be attributed to differences in comorbidity, such as ischaemic heart
15 disease, our observations from people with heart failure and no major comorbidity still
16 show clear differences in the outcomes of men and women. Notably, the survival of
17 women without major comorbidity overlapped with that of the matched general
18 population (**Figure 3**). The mechanisms of this sexual dimorphism remain debated
19 (13,14), but it is clear that clinical trials and guidelines should carefully consider the
20 differences between men and women with heart failure.

21

22 *Limitations*

23 Although our work has key strengths, it is important to acknowledge limitations that
24 should be addressed by ongoing research. First, we have deliberately chosen not to
25 derive an individualised risk assessment tool, as the aim of this paper is to describe

1 survival relative to life expectancy in populations with heart failure. However, our
2 methods could easily be used to extend the data provided by individualised prognostic
3 models, such as SHFM and MAGGIC (10,11). It will also be important to understand
4 whether health care professionals and patients find survival estimates relative to
5 actuarial life expectancy more useful than absolute survival estimates. Next, our data
6 should not be generalised to other populations (e.g. heart failure with preserved
7 ejection fraction), but our methods could easily be applied to published datasets. It is
8 also important that our 11-year follow-up period represents a modest proportion of
9 predicted life expectancy in our youngest participants, so caution should be applied in
10 extrapolating our data to the youngest people with heart failure. Finally, it is important
11 to note that our expected survival data are derived from the UK general population
12 which will include some people with heart failure; therefore, loss of expected survival
13 is in relation to the age-sex matched general population, not an age-sex matched heart
14 failure free population.

15

16 *Conclusions*

17 By framing survival in the context of actuarial predictions, we have shown that people
18 with heart failure with reduced left ventricular ejection fraction lose 2.4-fold more of life
19 than expected. However, most of this loss of life expectancy is accounted for by people
20 with comorbidity, particularly in women. Our work provides a different framework for
21 clinicians and people with heart failure to consider prognosis and should prompt more
22 focus on the issue of heart failure associated with complex multimorbidity.

23

24

25

26

1 **Abbreviations**

2	ACEi	Angiotensin converting enzyme inhibitors
3	ARB	Angiotensin receptor blockers
4	β -blockers	β -adrenoceptor antagonists
5	CHF	Chronic heart failure
6	CRT	Cardiac resynchronisation therapy
7	ICD	Implantable cardioverter-defibrillator
8	CKD	Chronic kidney disease
9	COPD	Chronic obstructive pulmonary disease
10	eGFR	Estimated glomerular filtration rate
11	EHRs	Excess hazard ratios
12	LVEF	Left ventricular ejection fraction
13	MAGGIC	Meta-analysis Global Group in Chronic Heart Failure
14	NYHA	New York Heart Association
15	SHFM	Seattle Heart Failure Model
16	UK	United Kingdom
17	UK-NLT	United Kingdom National Life Tables
18		



1 **References**

- 2 1. Metra M, Teerlink JR. Heart failure. *Lancet* 2017; 390(10106): 1981–95.
- 3 2. Conrad N, Judge A, Tran J, Mohseni H, Hedgecote D, Crespillo AP, Allison M,
4 Hemingway H, Cleland J, McMurray J, et al. Temporal trends and patterns in
5 heart failure incidence: a population-based study of 4 million individuals.
6 *Lancet* 2018; 391(10120): 572–80.
- 7 3. Benbarkat H, Addetia K, Eisenberg MJ, Sheppard R, Filion KB, Michel C.
8 Application of the Seattle Heart Failure Model in Patients >80 Years of Age
9 Enrolled in a Tertiary Care Heart Failure Clinic. *Am J Cardiol* 2012; 110(11):
10 1663–6.
- 11 4. Walker A, Drozd M, Hall M, Patel P, Paton M, Lowry L, Gierula J, Byrom R,
12 Kearney L, Sapsford R, et al. Prevalence and Predictors of Sepsis Death in
13 Patients With Chronic Heart Failure and Reduced Left Ventricular Ejection
14 Fraction. *J Am Hear Assoc* 2018; 7(20): e009684.
- 15 5. Cubbon RM, Gale CP, Kearney LC, Schechter C, Brooksby W, Nolan J, Fox K,
16 Rajwani A, Baig W, Groves D, et al. Changing characteristics and mode of
17 death associated with chronic heart failure caused by left ventricular systolic
18 dysfunction: a study across therapeutic eras. *Circ Hear Fail* 2011; 4(4): 396–
19 403.
- 20 6. Allen L, Yager J, Funk M, Levy W, Tulsy J, Bowers M, Dodson G, O'Conner
21 C, Felker M. Discordance between patient-predicted and model-predicted life
22 expectancy among ambulatory patients with heart failure. *JAMA* 2008;
23 299(21): 2533–42.
- 24 7. Levey A, Stevens L, Schmid C, Zhang Y, Castro A, Feldman H, Kusek J,
25 Eggers P, Van Lente F, Greene T, et al. A New Equation to Estimate

- 1 Glomerular Filtration Rate. *Ann Int Med.* 2009; 150(9): 604–12.
- 2 8. Lang RM, Bierig M, Devereuz R, Flachskampf F, Foster E, Pellikka PA,
3 Pichard M, Roman M, Seward J, Shanewise J, et al. Recommendations for
4 Chamber Quantification: A Report from the American Society of
5 Echocardiography’s Guidelines and Standards Committee and the Chamber
6 Quantification Writing Group, Developed in Conjunction with the European
7 Association of Echocardiograph. *J Am Soc Echocardiogr.* 2005; 18: 1440–63.
- 8 9. UK Government. United Kingdom National Life Tables. Accessed Nov 2018.
9 [https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarria](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables)
10 [ges/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables)
- 11 10. Pocock SJ, Ariti CA, McMurray JJ V, Maggioni A, Køber L, Squire I, Swedberg
12 K, Dobson J, Poppe K, Whalley G, et al. Predicting survival in heart failure: a
13 risk score based on 39 372 patients from 30 studies. *Eur Hear J* 2013; 34(19):
14 1404–13.
- 15 11. Levy WC, Mozaffarian D, Linker DT, Sutradhar S, Anker S, Cropp A, Anand I,
16 Maggioni A, Buron P, Sullivan M, et al. The Seattle Heart Failure Model:
17 prediction of survival in heart failure. *Circulation* 2006; 113(11): 1424–33.
- 18 12. Vaduganathan M, Claggett BL, Jhund PS, Cunningham J, Ferreira J, Zannad
19 F, Packer M, Fonarow G, McMurray J, Solomon S. Estimating lifetime benefits
20 of comprehensive disease-modifying pharmacological therapies in patients
21 with heart failure with reduced ejection fraction: a comparative analysis of
22 three randomised controlled trials. *Lancet.* 2020; 6736(20): 1–8.
- 23 13. Heidecker B, Lamirault G, Kasper EK, Wittstein I, Champion H, Breton E,
24 Russell S, Hall J, Kittleson M, Baughman K, et al. The gene expression profile
25 of patients with new-onset heart failure reveals important gender-specific

- 1 differences. Eur Hear J 2010; 31(10): 1188–96.
- 2 14. Levinsson A, Dubé MP, Tardif JC, Denus S. Sex, drugs, and heart failure: a
- 3 sex-sensitive review of the evidence base behind current heart failure clinical
- 4 guidelines. ESC Hear Fail 2018; 5(5): 745–54.
- 5
- 6

1




2

3

4 **Figure 1: Absolute and relative survival of the study cohort**

5 Legend: **A**) Kaplan-Meier curve illustrating cohort survival (solid line with grey 95% confidence interval); **B**) Relative survival curve
6 illustrating excess mortality in cohort (solid line with grey 95% confidence interval) and projected mortality in an age-sex matched
7 reference control population (dashed line).

1



2

3


4

5 **Figure 2: Relative survival stratified by gender**

6 Legend: Relative survival curves illustrating excess mortality in men and women (red
7 and blue solid lines, respectively, with grey 95% confidence intervals) and projected
8 mortality in an age matched reference control population (red and blue dashed lines,
9 respectively).

10

1



2

3

4

5 **Figure 3: Loss of expected life according to sex and number of co-morbidities**

6 Legend: Loss of expected life over 10-years of follow-up, with 95% confidence

7 interval, in men (red) and women (blue) according to number of comorbidities (from

8 ischaemic heart disease, chronic obstructive lung disease, diabetes, and chronic

9 kidney disease stage 4 or above).

Table 1: Participant characteristics

	Total cohort (n=1794)	Men (n=1311)	Women (n=483)	p value
Age (years)	69.6 (12.5)	69.3 (12.1)	70.4 (13.5)	0.1
Male sex (n [%])	1311 (73.1)	N/A	N/A	N/A
Ischaemic aetiology (n [%])	1064 (59.3)	835 (63.7)	229 (47.4)	<0.001
Diabetes (n [%])	504 (28.1)	384 (29.3)	120 (24.8)	0.06
COPD (n [%])	283 (15.8)	195 (14.9)	88 (18.2)	0.09
CKD 4 or above (n [%])	141 (7.9)	86 (6.6)	55 (11.4)	0.001
NYHA class 3/4 (n [%])	551 (30.7)	386 (29.5)	165 (34.2)	0.06
LV ejection fraction (%)	32 (9.5)	31.7 (9.5)	32.6 (9.5)	0.08
Betablocker use (n [%])	1516 (84.7)	1117 (85.5)	399 (82.6)	0.14
Bisoprolol equivalent dose (mg/day)	3.9 (3.4)	4 (3.4)	3.5 (3.3)	0.01
ACEi or ARB use (n [%])	1618 (90.4)	1195 (91.4)	423 (87.6)	0.014
Ramipril equivalent dose (mg/day)	4.9 (3.5)	5.1 (3.6)	4.3 (3.4)	<0.001
MRA use (n [%])	684 (38.2)	507 (38.8)	177 (38.8)	0.41
Furosemide equivalent dose (mg/day)	51 (50)	52 (52)	49 (43)	0.18
CRT (n [%])	452 (25.2)	353 (26.9)	99 (20.5)	0.005
ICD (n [%])	209 (11.6)	184 (14)	25 (5.2)	<0.001

Continuous data displayed as mean (standard deviation) and categorical data as number (%). COPD – chronic obstructive pulmonary disease; CKD – chronic kidney disease; NYHA – New York heart association; ACEi – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; MRA – mineralocorticoid receptor antagonist; CRT – cardiac resynchronisation therapy; ICD – implantable cardioverter-defibrillator.

Table 2: Multivariate survival analysis

	EHR	95% CI of EHR		p-value
		Low	High	
Diabetes	1.78	1.44	2.20	<0.001
COPD	2.58	2.06	3.24	<0.001
Ischaemic aetiology	1.42	1.13	1.78	0.004
CKD 4 or above	2.77	2.10	3.66	<0.001
Baseline	0.053	0.048	0.060	<0.001

Excess hazard ratios describe risk of reduced life expectancy relative to actuarial projections. CI – confidence interval; EHR – excess hazard ratio; COPD – chronic obstructive pulmonary disease; CKD – chronic kidney disease.

Declarations

Ethics approval and consent to participate The Leeds West Research Ethics Committee provided ethical approval (07/Q1205/17), and all patients provided written informed consent to participate

Consent for publication Not applicable

Availability of data and materials The datasets generated and/or analysed during the current study are not publicly available due to inclusion of potentially identifying postal codes, but are available from the corresponding author on reasonable request.

Competing interests JG has received a research grant from Medtronic. KKW has received speaker fees from Medtronic, Livanova, St. Jude Medical, Pfizer, Bayer and BMS. MTK has received speaker fees from Merck, NovoNordisk and unrestricted research awards from Medtronic. ADS has received speaker fees from Abbott, BMS, AstraZeneca, Bayer, Novartis, Boehringer Ingelheim and Servier. VKG has received speaker fees from Abbott and Novartis. All other authors have no disclosures.

Funding British Heart Foundation (PG/08/020/24617). MD and TS hold British Heart Foundation Clinical Research Training Fellowships. MP and JG hold National Institute of Health Research Fellowships. KKW holds a National Institute of Health Research Clinician Scientist Fellowship. MTK is a British Heart Foundation Professor and RMC was a British Heart Foundation Intermediate Clinical Fellow.

Authors' contributions MD collected data, analyzed data and drafted the manuscript. SDR collected data, analyzed data and drafted the manuscript. AMNW collected data and drafted the manuscript. TS collected data and critically revised the manuscript. JG collected data and critically revised the manuscript. MFP collected data and critically revised the manuscript. JL collected data and critically revised the manuscript. SS collected data and critically revised the manuscript. AK collected data and critically revised the manuscript. MG collected data and critically revised the manuscript. ADS collected data and critically revised the manuscript. VKG collected data and critically revised the manuscript. RJS collected data and critically revised the manuscript. KKW

collected data and critically revised the manuscript. MTK collected data and critically revised the manuscript. RMC collected data, analyzed data, and drafted the manuscript.

Acknowledgements

We are grateful for support from the NIHR funded clinical research facility at Leeds Teaching Hospitals NHS Trust.